BPC-157 is a synthetic 15-amino-acid peptide studied mostly in animals for tissue and gut healing. It has no identified receptor after roughly 230 published papers, about 77 percent of which come from one laboratory. Its human evidence is three uncontrolled reports from a single Florida clinic, totaling 31 patients. It is not approved for any use.
Ask about BPC-157
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Synthetic 15-amino-acid fragment, marketed as a “body protection compound” |
| Primary research interest | Tissue and gut healing, angiogenesis (blood-vessel formation) |
| Highest available evidence | Tier 2: uncontrolled human case series from one clinic (31 patients total) |
| Human research available | Limited: three uncontrolled papers, shared first author and journal |
| Development status | Unapproved research chemical; never entered a registered drug pipeline |
| Regulatory status | Not approved as a drug in the United States, European Union, or elsewhere; named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval) |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | BPC-157 |
| Alternative names | Body Protection Compound-157, Bepecin, PL-10, PL 14736; sold as pentadeca arginate (PDA), an arginine salt of the same sequence |
| Peptide sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
| Amino-acid length | 15 |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ (free peptide) |
| Molecular weight | ≈1419.5 g/mol (free peptide) |
| CAS Registry Number | 137525-51-0 |
| PubChem CID | 9941957 |
| Peptide class | Synthetic peptide fragment; marketed as derived from a gastric protective protein, though that parent protein has never been independently isolated or sequenced |
| Primary biological target | No receptor identified; proposed pro-angiogenic (VEGFR2/nitric-oxide pathway) effects reported by one research group |
| Developer / originator | Originally described by a Croatian research group (Sikiric et al.) |
| Development status | Unapproved research chemical, sold as a dietary/research product; not in any recognized clinical pipeline |
What it is
BPC-157 is a synthetic chain of fifteen amino acids, sequence GEPPPGKPADDAGLV. It is almost always described as a fragment of a naturally occurring human protein, and that description does not survive checking.
The claim traces to one sentence in a 1993 paper from the group that named the compound, reporting a 40 kDa gastric protein isolated and a fifteen amino acid fragment characterised (Sikiric 1993). No publication reporting that protein isolation, purification or sequencing exists, and it has no UniProt or GenBank accession. The only primary description is a 1994 US patent, which an independent review found describes only crude chromatography and dialysis.
So the accurate description is narrower: a synthetic peptide claimed to correspond to a fragment of a protein nobody has characterised. Reviews published in 2025 and 2026 still call it naturally occurring.
The form sold as pentadeca arginate, or PDA, is the same sequence with arginine as the counter-ion instead of acetate. A salt, not a different peptide. No peer-reviewed study of it exists and the FDA review did not evaluate it.
How it works
No receptor has been identified, no binding affinity measured, and no knockout or knockdown experiment has demonstrated a required target. After roughly thirty-four years and about 230 papers, the molecular target is unknown. That constrains everything else on this page.
The vascular finding is the one that has held up
A group at Chang Gung University in Taiwan reported that BPC-157 raises VEGFR2 expression and activates a VEGFR2 to Akt to eNOS pathway, improving blood flow recovery in rat hindlimb ischaemia (Hsieh 2017), and separately reported nitric-oxide-mediated relaxation of isolated rat aorta (Hsieh 2020). In 2026 an unrelated Turkish group reproduced that relaxation in human arterial tissue, using internal mammary artery rings from twelve donors (Bilgic 2026).
Two unaffiliated groups, two species, one converging result. This is the only claim in the BPC-157 literature that meets an ordinary standard of independent replication.
Beyond that, the measured findings are mostly cell culture, and the broader framework claim, that BPC-157 works through a general interaction with the nitric oxide system, is asserted across dozens of papers from the originating group rather than demonstrated by any single experiment.
Potential benefits and research applications
Tendon, ligament and muscle healing
What is being investigated: whether BPC-157 speeds recovery from tendon, ligament and muscle injury. How the effect might occur: proposed effects on fibroblast activity and the FAK-paxillin pathway (Chang 2011), though no receptor has been confirmed. Evidence: extensive animal data from one dominant laboratory; the first independent in vivo test of the flagship tendon claim (Bicer 2026) did not reach significance on any primary measure. Strength: has been reported in animal models; has not been independently replicated for tendon healing specifically. Limitation: no controlled human trial of any musculoskeletal injury exists.
Gut and gastrointestinal healing
What is being investigated: ulcer, colitis and intestinal-repair effects, the compound’s original research context. How the effect might occur: proposed gastroprotective and anti-inflammatory mechanisms, unconfirmed at the receptor level. Evidence: two controlled human studies exist (an ulcerative colitis RCT and a healthy-volunteer tolerability study), both published only as conference abstracts, plus extensive animal data. Strength: the human ulcerative colitis result showed a numerical difference from placebo with overlapping confidence intervals, not a clear separation. Limitation: FDA reviewed this data and called it inadequate to support efficacy or safety.
Blood flow and vascular effects
What is being investigated: whether BPC-157 improves blood flow via VEGFR2/Akt/eNOS signaling. How the effect might occur: raised VEGFR2 expression and nitric-oxide-mediated vessel relaxation. Evidence: this is the one claim in the BPC-157 literature independently replicated by an unaffiliated group, across two species (Hsieh 2017, Hsieh 2020, Bilgic 2026). Strength: has been shown in animal models and isolated human arterial tissue; not tested as a clinical outcome in a living person. Limitation: a lab finding, not a demonstrated patient benefit.
Joint and localized injection use (community-reported)
What is being investigated: intra-articular injection for chronic joint pain. Evidence: one retrospective chart review, 12 patients on BPC-157 alone, no control group, outcomes recalled by phone 6-12 months later. Strength: has been reported anecdotally in a clinical case series; has not been established in a controlled trial.
Research evidence
Human evidence: one clinic, thirty-one patients
Three published papers report giving BPC-157 to people and recording an outcome. All three share a first author and a journal.
- A retrospective chart review of intra-articular injection for knee pain. Seventeen patients, sixteen reached by telephone, only twelve of those on BPC-157 alone, rating pain from memory six months to a year later. The paper states that no specific tools were used to measure function, quality of life or stiffness. No control group (Lee 2021).
- A single-arm report in interstitial cystitis. Twelve women, no control group, 10 mg injected around the inflamed bladder area during cystoscopy, one procedure. Ten of twelve rated their symptoms fully resolved on a five-point subjective scale (Lee 2024).
- An intravenous safety pilot in two people, 10 mg then 20 mg. The paper notes that both participants had already received intravenous BPC-157 before enrolling (Lee 2025).
Independent 2026 reviews reach the same conclusion. A scoping review in sports medicine found human data limited to a handful of uncontrolled investigations and called claimed musculoskeletal benefits unsubstantiated. A review of rodent ischemia-reperfusion work found the evidence heterogeneous, mostly single-dose and short-term, and called BPC-157 a hypothesis-generating candidate, not an established therapy.
The cystitis result deserves a second look rather than a citation. Cystoscopy with bladder distension is itself associated with temporary relief in interstitial cystitis, so in a single-arm design with a subjective endpoint the procedure and the compound cannot be separated. The paper does not raise this.
Across all three, roughly thirty-one patients, none with a control group, every outcome self-reported, and all of it from one physician in Orlando, Florida.
The two controlled studies that are rarely mentioned
Two earlier human studies had a placebo arm, and both are absent from most popular accounts. Neither was published in full, so neither has a PubMed record, and both are visible only through the FDA briefing document.
- A randomised, placebo-controlled trial in mild to moderate ulcerative colitis. Fifty-three randomised, forty-six completed, 80 mg by rectal enema once daily for two weeks. Disease activity index change was minus 3.2 on BPC-157 against minus 1.6 on placebo, with confidence intervals that overlap. Conference abstract only.
- A tolerability study in twenty-four healthy volunteers, rectal enema up to 2 mg/kg daily for eight days. The reported result: BPC-157 was not detected in plasma samples. Conference abstract only.
That second finding is the only human measurement of whether BPC-157 reaches the circulation by any route, and it sits awkwardly beside a compound taken for systemic effect. FDA called the randomised data inadequate to support efficacy or safety.
Preclinical evidence
The animal and cell literature is large and reports benefit across an unusually wide range of models: gastric and duodenal ulcer, colitis, oesophagitis, intestinal anastomosis, short bowel syndrome, several fistula models, Achilles transection, tendon-to-bone detachment, transected quadriceps, ligament transection, traumatic brain injury, spinal cord compression, cerebral ischaemia, thrombosis and portal hypertension.
The breadth is itself a finding. A compound with no identified receptor improving outcomes in nearly every tissue and nearly every injury model is a pattern that calls for a mechanism, and none has been offered that would predict it.
The concentration problem
Of 230 papers indexed in PubMed on BPC-157, about 176, roughly 77 percent, carry Predrag Sikiric of the University of Zagreb as an author. Around 143 of those are primary research reports from that group. Sven Seiwerth, the group pathologist, appears on 163 of the 230. Counting carefully through the remainder, about fifteen papers, roughly 6.5 percent of the corpus, are primary biological studies by a group with no connection to Zagreb or to Pliva, the Croatian pharmaceutical company that licensed the compound.
Thirty-plus years, dozens of journals, one laboratory. That is not an accusation. It is why the independent work matters more than its volume suggests.
The first independent test of the tendon claim
Tendon healing is the claim BPC-157 is best known for, and until 2026 no unaffiliated group had tested it in a live animal. In July 2026 a Turkish group transected and repaired the Achilles tendon in thirty-two rats, giving BPC-157 at 10 micrograms per kilogram per day intraperitoneally, the exact dose and route of the original Zagreb work, for four weeks (Bicer 2026).
BPC-157 did not reach statistical significance on maximum load to failure, on the total Bonar score, or on the total Movin score, and showed no significant difference in collagen type I expression. The authors describe numerically lower scores that did not reach significance. TB-500, included as a comparator in the same experiment, did reach significance on all three.
One study is one study, and a single negative result settles nothing that the positive results have not settled either. It is here because it is the first independent in vivo attempt at the flagship claim, at the originators own dose.
| Reported use | Route | Amount reported | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|
| Human research (mixed indications) | Rectal enema, intra-articular, local injection, IV infusion | 2–4 mg (intra-articular) up to 80 mg (rectal enema); 10–20 mg (IV) | Varies by study | Varies by study | 5 published human studies, largely one clinic/author group, not validated |
| Animal research (Zagreb group) | Not specified / systemic | 10 µg, 10 ng, and 10 pg per kg: reported as equally effective (“equipotent”) across a million-fold range | Varies by study | Varies by study | Animal, single research group, no independent replication, no mechanistic explanation for the flat dose-response |
| General use (as commonly circulated online) | Subcutaneous | 250 mcg once or twice daily | Once or twice daily | 4–8 week blocks | Community / vendor reported: widely repeated online, but its original source could not be verified; not a validated human translation |
The dose that does not behave like a dose
The standard design in the Zagreb animal work gives three doses in the same experiment: 10 micrograms, 10 nanograms and 10 picograms per kilogram, a range spanning one million fold. Comparable benefit is reported at all three, and the group calls this an equipotent dosage, framing it as a property of the compound.
A receptor-mediated agent with a flat response across six orders of magnitude has no standard pharmacological interpretation. No independent group has tested it and no mechanistic account of it has been published.
The practical consequence matters more than the puzzle. Every dose conversion in circulation is built on those animal figures, and if 10 picograms per kilogram works as well as 10 micrograms, there is no dose to convert.
Safety
There is no human safety data at any duration beyond two weeks, by any route. The longest documented human exposure anywhere in the record is the two-week enema study described above.
The FDA gap list from the July 2026 advisory committee is specific. No acute toxicity study by any nominated route, meaning oral, rectal, subcutaneous or nasal. No repeat-dose toxicity by any of those routes, the only such data being a 28-day intramuscular set. No carcinogenicity study identified at all, which for an agent that raises VEGFR2 and promotes vessel growth is the most consequential absence on the list.
The 28-day intramuscular studies did produce signals: shortening and prolongation of activated partial thromboplastin time in rats and dogs, which FDA described as suggestive of altered clotting properties, together with raised ALT, glucose and triglycerides.
Immunogenicity has not been assessed in any species, and FDA said the risk could not be ruled out given aggregation potential and missing impurity testing. Three FAERS reports involve injectable BPC-157, including diffuse hyperpigmentation with gingival darkening that recurred on re-use.
The originating group states in its reviews that no toxicity has been observed and that a lethal dose could not be reached. FDA reviewed the same material and did not accept it as adequate.
Regulatory status
BPC-157 is not an approved drug anywhere. No approved products, no pending applications, and no entry in the European, Japanese or International Pharmacopoeias.
It was nominated for the 503A bulk drug substances list in 2015 and 2018, placed in Category 2 in 2023 for immunogenicity and impurity concerns, and removed from that category in April 2026 because the nominations had been withdrawn. Removal does not make a substance eligible for compounding.
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it, against FDA staff, eight to six with one abstention, in a single grouped vote that also covered KPV and TB-500 rather than a vote on BPC-157 alone (one secondary analysis records eight to seven). FDA reviewers had found no evidence of effectiveness for the nominated indication, ulcerative colitis, and no study using the oral, subcutaneous, nasal or transdermal route in those patients. As of mid-August 2026 reporting, FDA had not acted on the vote. The vote is non-binding, and listing on the 503A bulks list would still require a proposed rule, public comment and a final rule. HHS then published the separate interim notice summarized below. Law-firm guidance since the meeting advises pharmacies not to treat the vote as permission to compound.
On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). BPC-157 is one of six peptides named, listed as BPC-157 acetate, with subcutaneous, intramuscular, oral and topical use as the routes in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” Oral products would also need documentation of adequate bioavailability. It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add BPC-157 to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. It adds no new human evidence, and the evidence assessment on this page is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.
BPC-157 is not named individually on the WADA prohibited list but falls under class S0, non-approved substances, by the category definition. It is detectable in urine along with five metabolites.
Handling and identity
FDA found BPC-157 not well characterised physically or chemically, partly because the naming is inconsistent. Body Protection, Body Protective and Body Protecting Compound all appear in peer-reviewed papers for the same substance, as do the codes PL-10, PLD-116, PL 14736 and AK-15. BPC-15 is a different compound, and papers treating it as BPC-157 evidence are over-reading.
Per FDA, the lyophilised free base keeps about three weeks at room temperature, storage recommended below minus 18 degrees; in solution, two to three weeks at 4 degrees and three to four months at minus 20. It is sensitive to pH and heat, which drives aggregation.
Elimination half-life in rats and dogs is under thirty minutes, intramuscular bioavailability 14 to 19 percent in rats and 45 to 51 percent in dogs. No oral or subcutaneous figure exists in any species, which is worth holding next to the claim that the arginate form is 90 percent orally bioavailable. That figure appears in no peer-reviewed paper.
Frequently asked questions
What is BPC-157?
A synthetic 15-amino-acid peptide, commonly described as derived from a gastric protein, though no publication has isolated, purified or sequenced that parent protein.
How does it work?
Unknown at the receptor level. No receptor has been identified after roughly 230 published papers.
What dosage has been studied in humans?
Five human studies exist, spanning rectal enema (up to 80 mg), intra-articular injection (2-4 mg), local injection during a procedure (10 mg), and intravenous infusion (10-20 mg). They do not agree with each other and none establishes a validated dose.
What dosage commonly circulates online?
Most often 250 mcg once or twice daily, subcutaneous, in 4-to-8-week blocks. Its original source could not be verified. Animal work reports the same effect across a million-fold dose range, so there is no validated way to translate it to people.
Has it been studied in humans?
Yes, but only in uncontrolled or abstract-only form: three published uncontrolled reports (31 patients total, one Florida clinic) and two unpublished controlled studies visible only in an FDA briefing document.
What side effects have been reported?
Human safety data extends only to two weeks. Animal data flagged altered clotting markers and elevated liver enzymes, glucose and triglycerides after 28 days of intramuscular dosing. Immunogenicity has not been assessed in any species.
Is BPC-157 approved for any use?
No. It is not an approved drug anywhere. An FDA advisory committee voted narrowly (8-6-1) in July 2026 to recommend it for compounding, against FDA staff’s own review; FDA has not acted on that recommendation.
How strong is the evidence overall?
Mixed. One finding (vascular/blood-flow effects) has genuine independent replication across species. Its best-known claim, tendon healing, failed its first independent test. Human evidence is uncontrolled and comes from a single source.
What remains unknown?
Its receptor or mechanism, whether it reaches human circulation by any studied route, its carcinogenicity potential, and anything about the arginate (“PDA”) salt form, which has no peer-reviewed study of its own.
Bottom line
BPC-157 is genuinely interesting because one specific mechanistic claim, its effect on blood vessel signaling, has held up under independent testing across two species, which is rare in this literature. Its more famous claims, especially tendon healing, rest overwhelmingly on work from one laboratory and failed their first independent animal test. Human evidence is real but thin: three uncontrolled case series from one clinic, plus two never-fully-published controlled studies that a federal reviewer called inadequate. What circulates as a “standard dose” traces to an animal finding that showed identical results across a million-fold dose range, which undermines the idea that any of it constitutes a validated human translation. It is not approved for any use, anywhere, and a July 2026 FDA advisory vote to allow it in compounding passed only narrowly against the agency’s own staff recommendation.
Every amount reported in humans, in rat studies and in online protocols, with sources and routes, is laid out in the BPC-157 dosage guide.
For the companion peptide often paired with it, see the TB-500 dosage guide.
For where BPC-157 and other peptides sit in the FDA compounding categories, see FDA peptide status.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Injury and recovery | Subcutaneous | 200 to 500 mcg | Once or twice daily | 4 to 8 weeks |
| Severe or post-surgical | Subcutaneous | 500 to 800 mcg | Once daily | 4 weeks |
| Gut complaints | Oral | 250 mcg to 1 mg | Once daily | 4 to 6 weeks |
| Joint or local | Intra-articular | 2 to 4 mg | One or two doses | Not specified |
| As part of the Wolverine blend | Subcutaneous | Varies by vendor | Not standardised | 4 to 12 weeks |
Circulating figures for BPC-157 are tightly clustered, and the injectable convention is the most consistent of any compound on this site: 250 micrograms once or twice daily, subcutaneous, in four to eight week blocks with a break in between. Weight-based versions appear as roughly 2.5 to 3.75 micrograms per kilogram twice daily, or a flat 10 micrograms per kilogram per day described as the animal reference standard.
That last phrase is where the arithmetic comes from, and it is worth following. The 10 micrograms per kilogram figure is real and does appear in the animal literature. What the conversion leaves out is that the same experiments administered 10 nanograms and 10 picograms per kilogram alongside it and reported comparable benefit at all three. The originating group calls this an equipotent dosage. A million-fold range producing the same result is not a dose-response curve, and a figure scaled from one end of it is not a translated dose.
The oral figures rest on a separate gap. Animal oral efficacy was reported at roughly 6 micrograms per kilogram per day delivered in drinking water, which is an efficacy observation rather than a bioavailability measurement. No oral bioavailability value exists for any species, and the 90 percent figure attached to the arginate form appears in no peer-reviewed paper.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- US Food and Drug Administration. BPC-157 (free base) and BPC-157 acetate. Briefing document, Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026. FDA media 193343
- Sikiric P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993. PMID 8298609
- Sikiric P, et al. Peptides having pharmaceutical activity. US Patent 5,288,708. 1994. US 5,288,708
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017. PMID 27847966
- Hsieh MJ, et al. Modulation of vascular tone by BPC157 through Src-Caveolin-1-eNOS. Sci Rep. 2020. PMID 33051481
- Vasorelaxant effect of BPC-157 in human internal mammary artery. J Clin Med. 2026. PMID 42123221
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon fibroblasts and the FAK-paxillin pathway. J Appl Physiol. 2011. PMID 21030672
- Comparison of BPC-157 and TB-500 on Achilles tendon healing in a rat model. Jt Dis Relat Surg. 2026. PMID 42542926
- Staresinic M, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2003. PMID 14554208
- Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PMID 20225319
- Pharmacokinetics and metabolism of BPC 157 in rats and beagle dogs. Front Pharmacol. 2022. PMID 36588717
- Cox HD, Eichner D. Detection of BPC-157 and its metabolites in human urine. Drug Test Anal. 2017. PMID 28035768
- Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013. PMID 22950504
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PMID 40131143
- An independent review of the BPC-157 literature and patent record. Pharmaceuticals. 2025. PMID 40005999
- US Food and Drug Administration. Ipamorelin acetate, 503B, listed 29 September 2023, citing immunogenicity risk and serious adverse events including death reported in the literature after intravenous administration. FDA Category 2
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. Scoping review. doi:10.1177/03635465261464420
- Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026;27(18). doi:10.3390/ijms27188344
Compare BPC-157 with related compounds
Research area: Tissue repair and recovery.